Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 4 435 JPY 0.68% Market Closed
Market Cap: 127.7B JPY
Have any thoughts about
Torii Pharmaceutical Co Ltd?
Write Note

Torii Pharmaceutical Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Torii Pharmaceutical Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Torii Pharmaceutical Co Ltd
TSE:4551
Current Portion of Long-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Current Portion of Long-Term Debt
ÂĄ624.1B
CAGR 3-Years
43%
CAGR 5-Years
29%
CAGR 10-Years
14%
Daiichi Sankyo Co Ltd
TSE:4568
Current Portion of Long-Term Debt
ÂĄ400m
CAGR 3-Years
-73%
CAGR 5-Years
-60%
CAGR 10-Years
-43%
Otsuka Holdings Co Ltd
TSE:4578
Current Portion of Long-Term Debt
ÂĄ191.2B
CAGR 3-Years
57%
CAGR 5-Years
20%
CAGR 10-Years
9%
Chugai Pharmaceutical Co Ltd
TSE:4519
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Current Portion of Long-Term Debt
ÂĄ307.3B
CAGR 3-Years
43%
CAGR 5-Years
47%
CAGR 10-Years
45%
No Stocks Found

Torii Pharmaceutical Co Ltd
Glance View

Market Cap
124.7B JPY
Industry
Pharmaceuticals

Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Intrinsic Value
3 292.36 JPY
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Torii Pharmaceutical Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
0 JPY

Based on the financial report for Sep 30, 2024, Torii Pharmaceutical Co Ltd's Current Portion of Long-Term Debt amounts to 0 JPY.

Back to Top